We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Eurofins Launches New Tests and Massive Capacity for Detecting and Monitoring New Variants of SARS-CoV-2

By HospiMedica International staff writers
Posted on 18 Jan 2021
Print article
Illustration
Illustration
Eurofins (Luxembourg) has launched various initiatives to support the health authorities’ programs for the detection and monitoring of increasingly diverse SARS-CoV-2 variants.

The potential higher infectivity of some new viral strains underlines the need to identify, trace and track mutations across the complete viral genome. Through Eurofins’ current COVID-19 testing and clinical diagnostics activities globally and its partnerships with leading pharmaceutical and vaccine companies, the Group is able to closely monitor the identification of new variants of SARS-CoV-2.

Eurofins is increasing the capacity for its ARTIC Next Generation Sequencing (NGS) to more than 5,000 full genomes per day. The company has also launched NovaType, a SARS-CoV-2 RT-PCR assay, clinically validated for the identification of the B.1.1.7 variant, first identified in the UK, and the B.1.351 variant, first identified in South Africa. The test has a short turn-around time, making it ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 or B.1.351 variant. NovaType is already available as a Laboratory Developed Test (LDT) in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.

NovaType is being made available to health authorities in a number of European countries for trial and potential inclusion in their monitoring programs in response to these new variants. The NovaType assay will also be launched as a Research Use Only (RUO) kit in Europe by the end of January 2021. Eurofins intends to add new detection capabilities to NovaType as additional variants appear. Additionally, the Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.

Related Links:
Eurofins 


Print article

Channels

Business

view channel
Illustration

Machine Learning Algorithm Identifies Deteriorating Patients in Hospital Who Need Intensive Care

Researchers have developed a machine learning algorithm that could significantly improve clinicians’ ability to identify hospitalized patients whose condition is deteriorating to the extent that they need... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.